
A Preemptive Prescription to Cyber Exposure Management
Organizations need to take a proactive approach to identify, prioritize and mitigate threats in real time. This means gaining visibility and control into all physical and virtual assets.
Organizations need to take a proactive approach to identify, prioritize and mitigate threats in real time. This means gaining visibility and control into all physical and virtual assets.
Heranova Lifesciences recently launched a noninvasive blood test to diagnose endometriosis. The standard diagnostic method is laparoscopy, which requires anesthesia, followed by histological confirmation. With its blood test, Heranova seeks to replace the diagnostic function of laparoscopy, thus reserving surgical intervention only for therapeutic purposes.
Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, consumer-oriented segment of its business, while also giving the diabetes unit more room to focus and compete in its own crowded market.
Allowing hospitals to repair the equipment they depend upon daily is not a step backward, but a reaffirmation of trust in the skilled and deeply committed professionals who already maintain the integrity of our healthcare systems.
In this episode of the MedCity Pivot Podcast, editor-in-chief Arundhati Parmar, speaks with Helix CEO James Lu about his company and how far precision medicine has come.
Startup finalists competed in four tracks: biopharma; devices and diagnostics; health tech aimed at consumers and self-insured employers; and health tech aimed at payers and providers. Investor judges in each track selected the winners.
Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never became a big part of the genetic testing company’s business, but it is getting a new life by joining Regeneron Genetics Center, a Regeneron subsidiary that analyzes genetic data for drug R&D.
ZEM Life is developing a smartwatch that can deliver Narcan to combat a fentanyl overdose.
Israeli cancer diagnostics startup SpotitEarly launched in the U.S. It is developing a test that uses AI and trained canines to analyze patients’ breath samples, with the goal of detecting cancer at its earliest stages. The company plans to begin selling the at-home test to U.S. consumers next year.
To prepare for an autonomous surgical future, medtech leaders should explore the practical implications of potential scenarios, and structure investment accordingly. The key is to develop a living roadmap that drives decisions on a day-by-day basis, drawing on macro- and micro-trends.
PurpleLab and Genentech executives will explore how to leverage real world data to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access — in a May 22 webinar.
In a webinar sponsored by fintech business Mercury, investors from Breyer Capital and MBX Capital shared their startup trend perspectives on AI, valuation, and alternative funding.
The trouble is that our technical colleagues know how to build beautiful products, but most have not worked within the four walls of healthcare, very seldom within the operating room. As a result, they do not know what will work or what is sufficient to drive engagement. What's needed is collaboration.
Teal Health received FDA approval for the first-ever at-home cervical cancer test, which seeks to give patients an alternative to the in-office pap smear. The test is already covered by four major payers in California.
Through a new partnership, Babyscripts members now have access to Withings BPM Pro 2, an FDA-cleared cellular blood pressure monitor.